• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Critical, Emergent and Pulmonary Care Classics

TRAPS: Rivaroxaban vs. Warfarin for Secondary Prevention in Antiphospholipid Syndrome [Classics Series]

byDeepti Shroff Karhade
June 23, 2022
in Critical, Emergent and Pulmonary Care Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. This study was halted prematurely due to an excess of thromboembolic and bleeding events in patients treated with rivaroxaban compared to warfarin.

2. There were no deaths from thromboembolic or bleeding events in either group.

Original Date of Publication: September 2018

Study Rundown: The Trial on rivaroxaban in AntiPhospholipid Syndrome (TRAPS) was halted early as data showed that secondary prevention with rivaroxaban in high-risk triple-positive patients with antiphospholipid (aPL) syndrome was associated with an excess of thromboembolic and bleeding events compared to warfarin. Thus, this trial showed that treatment with rivaroxaban in these patients was inferior to treatment with warfarin. Strengths of this study include the completeness of its dataset, with no patients lost to follow-up, and its characterization of thromboembolic and bleeding outcomes. However, this study is limited by its relatively small sample size, the fact that it was not blinded, and of course, its early termination. Furthermore, as this study was restricted to a very specific subset of high-risk patients with aPL syndrome, future research is needed to determine if these results are generalizable to all patients with aPL syndrome. Ultimately, warfarin remains the standard of treatment in high-risk patients with aPL syndrome, as rivaroxaban is associated with increased adverse clinical outcomes.

Click to read the study in Blood

In-Depth [randomized control trial]: The Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) sought to test whether rivaroxaban is non-inferior to warfarin for prevention of thromboembolic events in high-risk patients with aPL syndrome. The study included participants aged 18-75 who were triple positive for all 3 aPL tests (lupus anticoagulant, anti- cardiolipin antibodies, and anti– b2-glycoprotein I antibodies) and had a history of a previously documented thrombotic event (n = 120). Participants were randomized to receive rivaroxaban (n = 59) or warfarin (n = 61) and were followed for incidence of thromboembolic events, major bleeding, and vascular death. The trial was stopped prior to completion for an excess of events in the patients treated with rivaroxaban compared to warfarin (11 vs. 2, respectively, HR 6.7; 95%CI 1.5-30.5; p = 0.01). Events included ischemic stroke, myocardial infarction, and major bleeding. There were no venous thromboembolism events nor any deaths in the ‘as treated’ population for either the rivaroxaban nor the warfarin group.

RELATED REPORTS

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365–71.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiphospholipid syndromebleeding eventsrivaroxabanthromboembolicwarfarin
Previous Post

Human papillomavirus (HPV) vaccination rates have increased in recent years

Next Post

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

June 21, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

June 20, 2022
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
StudyGraphics

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 26, 2022
Most anticoagulants for venous thromboembolism similarly effective
Hematology

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 18, 2022
Next Post
Intensive rehabilitation not superior to traditional therapy for arm function after stroke

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

Masks for personal protection for SARS-CoV-2 infection

Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Positive parenting intervention may decrease child socioemotional problems

Children with complex chronic conditions represent approximately half of postoperative deaths in children undergoing tonsillectomy in 5 US states

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
  • #VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.